Teva Pharmaceutical Industries (TEVA) News
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
41.10+1.85 (+4.71%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TEVA news summary
We found 44 recent headlines mentioning Teva Pharmaceutical Industries (TEVA): 8 in the past week and 25 in the past 30 days, most often from Seeking Alpha, Nasdaq, GlobeNewswire. For price context, TEVA is up 4.71% at $41.10. The most recent story, "Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth Strategy", was published by Seeking Alpha on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Teva Pharmaceutical Industries headlines
- Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth StrategySeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives - SlideshowSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives TranscriptSeeking Alpha
- J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?JNJ heads into Q3 earnings with strong drug sales and new launches, but Stelara biosimilar competition and MedTech challenges could weigh on growth.NasdaqJNJ, AMGN, TEVA
- Teva Wins FDA Approval For Once-Monthly Schizophrenia Treatment WELTRUZA(RTTNews) - Teva Pharmaceuticals (TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved WELTRUZA (olanzapine) extended-release injectable suspension for the treatment of…Nasdaq
- FDA Approves Teva's Once-Monthly Injectable Olanzapine(RTTNews) - Friday, Teva Pharmaceuticals (TEVA) announced that the U.S. FDA has approved WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia.Nasdaq
- Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with SchizophreniaTeva will hold an investor call and live webcast on Friday, October 9, 2026, 8:00 a.m. ETGlobeNewswire
- iShares MSCI ACWI ex US ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ex US ETF (Symbol: ACWX) where we have detected an…NasdaqACWX, SPOT, TEVA, MSCI
- Teva's Ecopipam Shows Sustained Tic Reduction In Pediatric Tourette Syndrome(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a biopharmaceutical company, reported new clinical and mechanistic data for ecopipam, an investigational selective D1 dopamine receptor…Nasdaq
- Teva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA) presented new efficacy and safety data for ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist being…Nasdaq
- Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 19.98% to $0.13The average one-year price target for Teva Pharmaceutical Industries Limited - Depositary Receipt (NYSE:TEVA) has been revised to $0.13 / share, up 19.98% from the prior estimate of $0.11 dated…Nasdaq
- Teva and Samsung Bioepis partner on up to six biosimilarsSeeking Alpha
- Here's Why You Should Add URGN Stock to Your Portfolio NowUroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.NasdaqURGN, TEVA, ACIU, PGEN
- Teva's Branded Drugs Take Center Stage in Its Growth StrategyTeva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.NasdaqTEVA, SNY, AMRN, ACIU
- Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug TurnaroundKey PointsForecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year.Nasdaq
- Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA as a biosimilar to Xgeva (denosumab).Nasdaq
- iShares Core MSCI EAFE ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an…NasdaqIEFA, SPOT, TEVA, MSCI
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaTEVA, BAC
- Teva Eyes New Growth Phase After Securing Investment-Grade RatingsMarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major…Nasdaq
- Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference TranscriptSeeking Alpha
- Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth PipelineMarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a…Nasdaq
- Teva's UZEDY Linked To Fewer Emergency Visits And Lower Healthcare Costs In Real-World Study(RTTNews) - Teva Pharmaceutical Industries (TEVA) on Friday reported new real-world data showing that UZEDY helped patients with schizophrenia remain on treatment longer while reducing emergency room…Nasdaq
- Teva Presents Positive Post Hoc Data For TEV-'749 For Schizophrenia; FDA Decision In Q4 '26(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA), a generic drugs company, on Friday presented positive post-hoc data from the Phase 3 SOLARIS trial for TEV-'749 in treating schizophrenia. The…NasdaqLLY, TEVA
- IEFA, SPOT, TEVA, SE: Large Inflows Detected at ETFLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI EAFE ETF (Symbol: IEFA) where we have detected an…NasdaqIEFA, SPOT, TEVA
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaTEVA, MS
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study - SlideshowSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Positive Topline Results for Anti-IL-15 Antibody in Phase IIa Celiac Disease Study TranscriptSeeking Alpha
- Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized DrugmakersTrump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.NasdaqTEVA, BBIO, ONC
- Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' PlanSeeking Alpha
- Teva Pharmaceutical Industries Limited 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b - SlideshowSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b TranscriptSeeking Alpha
- Teva Pharmaceutical's Innovative Shift Continues With Ecopipam AdditionSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking AlphaTEVA, GS
- Teva's Growth Story Is No Longer Just Generic, It's Getting BrandedSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaTEVA, BAC
- Teva's CNS Portfolio Is Growing, But Valuation Is StretchedSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Teva Pharmaceutical Industries Limited 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Teva: Shedding The Generics Skin To Reveal A Fairly Priced, Branded PowerhouseSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking AlphaTEVA, BCS
- Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - SlideshowSeeking Alpha